NEW YORK (GenomeWeb News) – Waters today reported that its revenues in the first quarter were up 2 percent year over year, driven by a resurgence in instrument sales, particularly mass spectrometers.

The company posted revenues of $430.3 million, up from $420.5 million in Q1 2012, but short of the average Wall Street estimate of $432.4 million. Foreign currency translation lowered sales growth by 3 percent, Waters said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.